Update on key emerging challenges in cystic fibrosis

Medical Principles and Practice

Volumn 23, Issue 5, 2014, Pages 393-402

  Jennings, Mark T ^a   Riekert, Kristin A ^a   Boyle, Michael P ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Adherence; Cystic fibrosis; Cystic fibrosis transmembrane conductance regulator; Methicillin resistant Staphylococcus aureus

Indexed keywords

ANTIBIOTIC AGENT; CHLORIDE CHANNEL; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;

CHLORIDE TRANSPORT; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INFECTION COMPLICATION; LUNG CLEARANCE; LUNG FUNCTION; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW (TOPIC); TREATMENT REFUSAL; COMPLICATION; GENETICS; MEDICATION COMPLIANCE; MUTATION; STAPHYLOCOCCAL INFECTIONS;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; MEDICATION ADHERENCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MUTATION; STAPHYLOCOCCAL INFECTIONS;

EID: 84927689656     PISSN: 10117571     EISSN: 14230151     Source Type: Journal    
DOI: 10.1159/000357646     Document Type: Review

References (58)

1. Boyle MP: Adult cystic fibrosis. JAMA 2007; 298:1787-1793.
2. Cystic Fibrosis Foundation: Patient Registry, 2011 Annual Data Report. Bethesda, Cystic Fibrosis Foundation, 2012.
3. Mogayzel PJ, Naureckas ET, Robinson KA, et al: Cystic fibrosis pulmonary guidelines. Am J Respir Crit Care Med 2013; 187:680-689.
4. Ratjen F, Doring G: Cystic fibrosis. Lancet 2003; 361:681-689.
5. Flume P, O'Sullivan B, Robinson K, et al: Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176:957-969.
6. Udo EE: Community-acquired methicillin-resistant Staphylococcus aureus: the new face of an old foe? Med Princ Pract 2013, doi 10.11591000354201.
7. 1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008; 178:814-821.
8. Dasenbrook EC, Checkley W, Merlo CA, et al: Association between respiratory tract methi-cillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010; 303: 2386-2392.
9. Glikman D, Siegel J, David M, et al: Complex molecular epidemiology of methicillin-re-sistant Staphylococcus aureus isolates from children with cystic fibrosis in the era of epidemic community-associated methicillin-resistant S. aureus. Chest 2008; 133:1381-1387.
10. Molina A, Del Campo R, Maiz L, et al: High prevalence in cystic fibrosis patients of multi-resistant hospital-acquired methicillin-resis-tant Staphylococcus aureus ST228-SCCmecI capable of biofilm formation. J Antimicrob Chemother 2008; 62:961-967.
11. Besier S, Smaczny C, von Mallinckrodt C, et al: Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease. J Clin Micro-biol 2007; 45:168-172.
12. Kahl B, Herrmann M, Everding AS, et al: Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J Infect Dis 1998; 177: 1023-1029.
13. Elizur A, Orscheln RC, Ferkol TW, et al: Pan-ton-Valentine leukocidin-positive methicil-lin-resistant Staphylococcus aureus lung infection in patients with cystic fibrosis. Chest 2007; 131:1718-1725.
14. Doe SJ, McSorley A, Isalska B, et al: Patient segregation and aggressive antibiotic eradication therapy can control methicillin-resistant Staphylococcus aureus at large cystic fibrosis centres. J Cyst Fibros 2010; 9:104-109.
15. Macfarlane M, Leavy A, McCaughan J, et al: Successful decolonization of methicillin-re-sistant Staphylococcus aureus in paediatric patients with cystic fibrosis (CF) using a three-step protocol. J Hosp Infect 2007; 65: 231-236.
16. Garske LA, Kidd TJ, Gan R, et al: Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection. J Hosp Infect 2004; 56:208-214.
17. Solis A, Brown D, Hughes J, et al: Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol. Pediatr Pulmonol 2003; 36:189-195.
18. Konstan MW, VanDevanter DR, Rasouliyan L, et al: Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulm-onol 2010; 45:1167-1172.
19. Eakin MN, Bilderback A, Boyle MP, et al: Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros 2011; 10: 258-264.
20. Daniels T, Goodacre L, Sutton C, et al: Accurate assessment of adherence: self-report and clinician report vs. electronic monitoring of nebulizers. Chest 2011; 140:425-432.
21. Latchford G, Duff A, Quinn J, et al: Adherence to nebulised antibiotics in cystic fibrosis. Patient Educ Couns 2009; 75:141-144.
22. Faulkner C, Taper LJ, Scott M: Adherence to pancreatic enzyme supplementation in adolescents with cystic fibrosis. Can J Diet Pract Res 2012; 73:196-199.
23. Ball R, Southern KW, McCormack P, et al: Adherence to nebulised therapies in adolescents with cystic fibrosis is best on week-days during school term-time. J Cyst Fibros 2013; 12:440-444.
24. McNamara PS, McCormack P, McDonald AJ, et al: Open adherence monitoring using routine data download from an adaptive aerosol delivery nebuliser in children with cystic fi-brosis. J Cyst Fibros 2009; 8:258-263.
25. Briesacher BA, Quittner AL, Saiman L, et al: Adherence with tobramycin inhaled solution and health care utilization. BMC Pulm Med 2011; 11:5.
26. Wertz DA, Chang CL, Stephenson JJ, et al: Economic impact of tobramycin in patients with cystic fibrosis in a managed care population. J Med Econ 2011; 14:759-768.
27. Nasr SZ, Chou W, Villa KF, et al: Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis. J Med Econ 2013; 16:801-808.
28. Geller DE, Kesser KC: The I-neb Adaptive Aerosol Delivery System enhances delivery of alpha1-antitrypsin with controlled inhalation. J Aerosol Med Pulm Drug Deliv 2010; 23(suppl 1):S55-S59.
29. Hess LM, Raebel MA, Conner DA, et al: Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Phar-macother 2006; 40:1280-1288.
30. George M, Rand-Giovannetti D, Eakin MN, et al: Perceptions of barriers and facilitators: self-management decisions by older adolescents and adults with CF. J Cyst Fibros 2010; 9:425-432.
31. Bregnballe V, Schiotz PO, Boisen KA, et al: Barriers to adherence in adolescents and young adults with cystic fibrosis: a questionnaire study in young patients and their parents. Patient Prefer Adherence 2011; 5:507-515.
32. Bucks RS, Hawkins K, Skinner TC, et al: Adherence to treatment in adolescents with cystic fibrosis: the role of illness perceptions and treatment beliefs. J Pediatr Psychol 2009; 34: 893-902.
33. Dziuban EJ, Saab-Abazeed L, Chaudhry SR, et al: Identifying barriers to treatment adherence and related attitudinal patterns in adolescents with cystic fibrosis. Pediatr Pulmonol 2010; 45:450-458.
34. Simon SL, Duncan CL, Horky SC, et al: Body satisfaction, nutritional adherence, and quality of life in youth with cystic fibrosis. Pediatr Pulmonol 2011; 46:1085-1092.
35. Smith BA, Modi AC, Quittner AL, et al: Depressive symptoms in children with cystic fi-brosis and parents and its effects on adherence to airway clearance. Pediatr Pulmonol 2010; 45:756-763.
36. Haynes RB, Ackloo E, Sahota N, et al: Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008, p CD000011.
37. Kahana S, Drotar D, Frazier T; Meta-analysis of psychological interventions to promote adherence to treatment in pediatric chronic health conditions. J Pediatr Psychol 2008; 33: 590-611.
38. Savage E, Beirne PV, Ni Chroinin M, et al: Self-management education for cystic fibro-sis. Cochrane Database Syst Rev 2011, p CD007641.
39. Boucher RC: Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends Mol Med 2007; 13:231-240.
40. + channel. J Biol Chem 2010; 285: 32227-32232.
41. Boucher RC: Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med 2007; 261:5-16.
42. Kerem B, Rommens J, Buchanan J, et al: Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245:1073-1080.
43. Amaral M, Kunzelmann K: Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis. Trends Pharmacol Sci 2007; 28: 334-341.
44. Clunes M, Boucher R: Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis. Curr Opin Pharmacol 2008; 8:292-299.
45. Ramsey B, Davies J, McElvaney N, et al: A CFTR potentiator in patients with cystic fi-brosis and the G551D mutation. N Engl J Med 2011; 365:1663-1672.
46. Sloane P, Rowe S: Cystic fibrosis transmem-brane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis. Curr Opin Pulm Med 2010; 16:591-597.
47. CFTR2 Clinical and Functional Translation of CFTR, US CF Foundation, Johns Hopkins University, et al: http://www.cftr2.org/browse. php. 2011-2012. http://www.cftr2.org.
48. Davies JC, Li H, Yen K, et al: Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D-CFTR mutation (abstract). J Cyst Fibros 2012; 11:S13.
49. Yu H, Burton B, Huang C, et al: Ivacaftor po-tentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 2012; 11:237-245.
50. Flume P, Liou T, Borowitz D, et al: Ivacaftor in subjects with cystic fibrosis who are homo-zygous for the F508del-CFTR mutation. Chest 2012; 142:718-724.
51. Van Goor F, Straley K, Cao D, et al: Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2009; 106:18825-18830.
52. Boyle MP, Bell S, Konstan M, et al: The inves-tigational CFTR corrector, VX-809 (luma-caftor) co-administered with the oral poten-tiator ivacaftor improved CFTR and lung function in F508del homozygous patients: phase II study results. Pediatr Pulmonol 2012; 47:315.
53. Corbyn Z: Promising new era dawns for cystic fibrosis treatment. Lancet 2012; 379:1475-1476.
54. Du M, Liu X, Welch E, et al: PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci USA 2008; 105:2064-2069.
55. Welch E, Barton E, Zhuo J, et al: PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447:87-91.
56. Kerem E, Hirawat S, Armoni S, et al: Effectiveness of PTC124 treatment of cystic fibro-sis caused by nonsense mutations: a prospective phase II trial. Lancet 2008; 372:719-727.
57. Wilschanski M, Miller L, Shoseyov D, et al: Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 2011; 38:59-69.
58. Konstan M, Accurso F, De Boeck K, et al: Targeting class 1 mutations: update on ataluren as a promising treatment for nonsense mutation in CF. Pediatr Pulmonol 2012; 47:108-109.